oral RORy nuclear receptor antagonist on-going Ph. II for psoriasis (QD dosing) 50k cmpd high-conc. frag. screen + scaff. hop ACS Med. Chem. Lett., Jan. 5, 2021 Boehringer Ingelheim, Ridgefield, CT